Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

Shire news

29 Dec 2009 Director/PDMR Shareholding
23 Dec 2009 Dr Michael Rosenblatt to step down as non-executive director
22 Dec 2009 Shire Submits Biologics License Application (BLA) for REPLAGAL® with the U.S. Food and Drug Administration (FDA)
21 Dec 2009 Shire Expands its Award-Winning ADHD Support Resource, ADHDSupport.com, by Launching an ADHD Twitter™ Page
16 Dec 2009 Membership of Board Committees
16 Dec 2009 Director/PDMR Shareholding
14 Dec 2009 Director/PDMR Shareholding
11 Dec 2009 Director/PDMR Shareholding (18KB PDF)
07 Dec 2009 Notification of major interests in shares (32KB PDF)
04 Dec 2009 Non-safety-related voluntary recall of a limited portion of Daytrana® (methylphenidate transdermal system) patches announced
02 Dec 2009 Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
01 Dec 2009 Total Voting Rights
24 Nov 2009 Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
23 Nov 2009 Block listing six monthly return (25KB PDF)
12 Nov 2009 PDMR Shareholding
12 Nov 2009 Shire Reports Findings From an Analysis Examining Emotional Lability in Children With ADHD Taking VYVANSE® (lisdexamfetamine dimesylate) Capsules CII
11 Nov 2009 Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse® (lisdexamfetamine dimesylate) Capsules CII
04 Nov 2009 FDA Grants Priority Review for Shire’s velaglucerase alfa for Type 1 Gaucher Disease
03 Nov 2009 Directors/PDMR Shareholding
02 Nov 2009 Total Voting Rights
02 Nov 2009 New Shire Board member
30 Oct 2009 Shire Reports Tolerability and Clinical Effects Results of DAYTRANA® (methylphenidate transdermal system) from Study in Adolescents with ADHD
30 Oct 2009 Shire continues to deliver excellent growth from core products (354KB PDF)
28 Oct 2009 Shire Secures European Wide Label Extension for FOSRENOL® in Chronic Kidney Disease
26 Oct 2009 FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity
22 Oct 2009 Third quarter 2009 results date notification – October 30, 2009
21 Oct 2009 Shire Targets Fourth Quarter Filing of BLA for REPLAGAL® for Fabry Disease with U.S. FDA
19 Oct 2009 Shire voluntarily enables further access to HIV/AIDS medicines for Rwanda
15 Oct 2009 Holding(s) in Company (33KB PDF)
13 Oct 2009 Shire and Sandoz Settle All Pending Litigation Concerning ADDERALL XR®
07 Oct 2009 Data from a head-to-head crossover study evaluating FOSRENOL® and sevelamer published today
01 Oct 2009 Total Voting Rights (16KB PDF)
25 Sep 2009 Director/PDMR Shareholding
22 Sep 2009 Director/PDMR Shareholding
18 Sep 2009 Director/PDMR Shareholding
16 Sep 2009 Celebrity dancer, Karina Smirnoff, speaks out for the first time on how ADHD has impacted her life
08 Sep 2009 Update on velaglucerase alfa
04 Sep 2009 Director/PDMR Shareholding
03 Sep 2009 Director/PDMR Shareholding
01 Sep 2009 Total Voting Rights
01 Sep 2009 Elections for interim dividend in respect of the six months to June 30, 2009
01 Sep 2009 Shire Completes Submission of NDA for velaglucerase alfa for Type 1 Gaucher disease and Reports Positive Results for Remaining Two Phase III Trials
24 Aug 2009 Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
21 Aug 2009 Half Yearly Report
19 Aug 2009 Director/PDMR Shareholding (19KB PDF)
17 Aug 2009 Shire Initiates Two Adult ADHD Outreach Programs
07 Aug 2009 Membership of Board Committees
05 Aug 2009 Q2 results - Core portfolio of products delivers 20% sales growth (291KB PDF)
03 Aug 2009 Total Voting Rights
03 Aug 2009 Shire Reports Positive Results from First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions with FDA
22 Jul 2009 Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse® (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
21 Jul 2009 Second quarter 2009 results date notification – August 5, 2009
16 Jul 2009 Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
16 Jul 2009 Message from Sylvie Grégoire, President, Human Genetic Therapies regarding the MLD experimental drug
08 Jul 2009 Dr Jeffrey Leiden appointed to Vertex Board.
06 Jul 2009 Shire has filed a treatment protocol for velaglucerase alfa for Gaucher Disease
01 Jul 2009 Total Voting Rights
01 Jul 2009 Study Showed VYVANSE® (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
16 Jun 2009 New Study in Women with Fabry Disease, Demonstrates Significant Benefits of Treatment with REPLAGAL® (agalsidase alfa) 0.2mg/kg on Kidney Function, Heart Function and Burden of Disease
01 Jun 2009 Total Voting Rights
01 Jun 2009 FDA Approves Labeling Change for VYVANSE® (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD (36KB PDF)
26 May 2009 Block Listing Six Monthly Return (26KB PDF)
22 May 2009 Director/PDMR Shareholding
22 May 2009 New Study Evaluating the ADHD Medication VYVANSE® (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC® 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
21 May 2009 Results from a European Caregiver Survey Highlight the Impact of Attention Deficit Hyperactivity Disorder (ADHD) on the Child and the Family
15 May 2009 Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18
12 May 2009 Director/PDMR Shareholding (18KB PDF)
01 May 2009 Total Voting Rights
30 Apr 2009 Shire begins the year with a strong performance (175KB PDF)
28 Apr 2009 Results of the Annual General Meeting held on April 28, 2009 (20KB PDF)
20 Apr 2009 First quarter 2009 results date notification – April 30, 2009
02 Apr 2009 Shire files lawsuit against Natco Pharma for infringement of FOSRENOL® (lanthanum carbonate) patents
01 Apr 2009 Annual Information Update (28KB PDF)
01 Apr 2009 Director/PDMR Shareholding (19KB PDF)
01 Apr 2009 Notification of major interest in shares (90KB PDF)
01 Apr 2009 Total Voting Rights
31 Mar 2009 Shire and GlaxoSmithKline enter agreement to co-promote VYVANSE® (lisdexamfetamine dimesylate) CII for the treatment of adults with ADHD
25 Mar 2009 Publication of Shire plc's Annual Report 2008 (161KB PDF)
21 Mar 2009 Saving a playground, lifting a neighborhood
20 Mar 2009 Shire files lawsuit against Mylan for infringement of FOSRENOL® (lanthanum carbonate) patent
20 Mar 2009 Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA® (methylphenidate transdermal system) patches announced
19 Mar 2009 Holding(s) in Company (32KB PDF)
16 Mar 2009 Shire files lawsuit against Barr Laboratories for infringement of FOSRENOL® (lanthanum carbonate) patents
16 Mar 2009 Shire withdraws European Application for DAYTRANA™ (methylphenidate transdermal system)
12 Mar 2009 World Kidney Day press release
12 Mar 2009 Holding(s) in Company (33KB PDF)
09 Mar 2009 Holding(s) in Company (31KB PDF)
05 Mar 2009 Holding(s) in Company (34KB PDF)
02 Mar 2009 Elections for interim dividend in respect of the six months to December 31, 2008
02 Mar 2009 Total Voting Rights
26 Feb 2009 Shire HGT Announces Support for Rare Disease Day
23 Feb 2009 Director/PDMR Shareholding
23 Feb 2009 Director/PDMR Shareholding
20 Feb 2009 Shire to enter European ADHD market with the acquisition of EQUASYM® IR and XL
20 Feb 2009 Shire Announces Opening of Office in Japan
19 Feb 2009 Shire delivers excellent growth for the year, with the new product portfolio achieving sales of $1 billion
09 Feb 2009 Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
09 Feb 2009 Full Year 2008 results date notification – 19 February 2009
05 Feb 2009 Change to Director's details
02 Feb 2009 Total Voting Rights
05 Jan 2009 Total Voting Rights

Did you know...

We have developed a
version of this web site
that is suitable for your
portable device
.